| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Black Diamond Therapeutics, Inc.$1.91
+0.03 (+1.6%)
D 29Pipeline Score Overvalued Biotech · Clinical
Market Cap
124.92 M
EPS
-0.76
P/E Ratio
-2.88 $
Value Trade
1.79 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
7.00 M
Operating CF
-10.23 M
Total Assets
132.92 M
Total Liabilities
28.62 M
Equity
104.30 M
D/E Ratio
12,345
-19.15 %
Week
-28.75 %
1 Month
0 %
3 Month
-39.2 %
6 Month
-84.39 %
5 Year
-93.09 %
All Time
Cash Data
Cash Position
118.26 M
Monthly Burn
3.41 M
Runway
32.8 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.05 M
52 Week Range
1.93 - 4.94
% held by Insiders
19.69 %
% held by Institutions
48.55 %
Enterprise Value
24.54 M
Total Shares
57.31 M
Short %
10.62 %
Float Shares
42.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Black Diamond Therapeutics, Inc.
327Total events
8Upcoming
40Tier-1 (high impact)
2019 – 2028Coverage
Upcoming catalysts 8
Event history 319
Jun 3, 2026
◆Oral PresentationPresentation
CEO to participate in fireside chat at Jefferies Global Healthcare Conference
Jun 1, 2026
◆Poster Presentationsilevertinib monotherapyPresentation
Trial-in-progress poster presentation of randomized Phase 2 study of silevertinib in newly diagnosed GBM at ASCO 2026
EGFRvIII-positive IDHwt MGMT unmethylated glioblastomasource ↗
May 31, 2026
◆Poster Presentationsilevertinib monotherapyPresentation
Poster presentation of Phase 2 safety and efficacy data for silevertinib in previously treated NSCLC patients at ASCO 2026
non-small cell lung cancer with non-classical and C797S EGFR mutationssource ↗
May 30, 2026
◆Oral Presentationsilevertinib monotherapyPresentation
Oral presentation of Phase 2 safety and efficacy data for silevertinib in treatment-naïve NSCLC patients at ASCO 2026
non-small cell lung cancer with non-classical EGFR mutationssource ↗
May 21, 2026
◆Oral Presentationsilevertinib monotherapyPresentation
Webcast to present updated results from Phase 2 trial of silevertinib in 1L EGFRm NSCLC
EGFR mutated non-small cell lung cancersource ↗
May 21, 2026
▲Topline Readoutsilevertinib monotherapyClinical Data
Positive Phase 2 results for silevertinib in 1L NSCLC with EGFR-NCMs
frontline non-small cell lung cancer with EGFR non-classical mutationssource ↗
May 2026
▲First Patient Dosedsilevertinib monotherapyTrial
First patient dosed in Phase 2 trial of silevertinib in combination with TMZ in newly diagnosed EGFRvIII+ GBM
newly diagnosed EGFRvIII+ GBMsource ↗
May 2026
▲Trial Initiationsilevertinib monotherapyTrial
Initiation of randomized Phase 2 trial in GBM
newly diagnosed EGFRvIII-positive glioblastomasource ↗
Apr 14, 2026
Drug Pipeline Intelligence
D29
Pipeline Score $49M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.4x
rNPV / MCap Top 33%
Micro Cap (rank 611 of 911)
Percentile RankBlack Diamond Therapeutics, Inc. faces pipeline headwinds (29/100), with $196M risk-adjusted pipeline value, led by silevertinib monotherapy in Non-Small Cell Lung Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| silevertinib monotherapy Small molecule | Non-Small Cell Lung Cancer | Phase 1 | NCT05256290 | 5% | $196M | ACTIVE NOT_RECRUITING | 200 | FAST | D (38) | Jun 1, 2026 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
silevertinib | non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations | Phase 2 | 2026-05-21 | median progression free survival: 15.2 months; overall response rate: 60%; CNS ORR: 86%; median duration of response: not reached Read More | Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations Read More | |
silevertinib | non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations | Phase 2 | 2026-05-21 | median progression free survival: 15.2 months; overall response rate: 60%; CNS ORR: 86%; median duration of response: not reached Read More | Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations Read More | |
silevertinib | non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations | Phase 2 | 2026-05-21 | median progression free survival: 15.2 months; overall response rate: 60%; CNS ORR: 86%; median duration of response: not reached Read More | Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BDTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BDTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BDTX▼ -35.8%on this news
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics, a clinical-stage oncology company, will participate in the Jefferies Global Healthcare Conference on June 3, 2026. CEO Mark Velleca will engage in a fireside chat, and the company will also host one-on-one meetings with investors. The announcement highlights the company's focus on developing MasterKey therapies to target mutations in cancer patients. A webcast of the presentation will be available on their website, with a replay archived for 90 days.
Read more →BDTXBlack Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
Black Diamond Therapeutics announced positive Phase 2 results for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations. The trial showed a preliminary median progression-free survival of 15.2 months and a 60% overall response rate. Notably, there were no new brain metastases among patients, highlighting the drug's robust CNS activity. The company plans to discuss pivotal development plans with the FDA later this year.
Read more →BDTX▲ +16.3%on this news· ran to +40% by day 1shared move
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
Black Diamond Therapeutics will host a webcast on May 21, 2026, to present updated results from its Phase 2 trial of silevertinib for patients with EGFR mutated non-small cell lung cancer. The event aims to inform investors about the ongoing developments in the trial. A replay will be available post-event.
Read more →BDTXBlack Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its Q1 2026 financial results, highlighting the dosing of the first patient in a Phase 2 trial for EGFRvIII+ GBM. The company has a strong cash position of $118.3 million, sufficient to fund operations into the second half of 2028. Upcoming presentations at the 2026 ASCO Annual Meeting will showcase data on silevertinib for NSCLC and GBM.
Read more →BDTXDocument Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR a
Black Diamond Therapeutics has announced its financial results for Q1 2026, reporting a net loss of $9 million compared to a profit in the same period last year. The company has sufficient cash reserves of $118.3 million to sustain operations until the second half of 2028. Notably, they plan to present Phase 2 data on silevertinib for EGFRm NSCLC patients at the upcoming ASCO Annual Meeting, alongside initiating a Phase 2 trial for EGFRvIII+ GBM. The financial results reflect a lower cash position and shift in focus to clinical trials for their lead compound, silevertinib.
Read more →BDTXBlack Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Black Diamond Therapeutics announced multiple presentations at the 2026 ASCO Annual Meeting, including an oral presentation on the Phase 2 study of silevertinib in treatment-naïve patients with non-small cell lung cancer (NSCLC) featuring non-classical EGFR mutations. The company also plans to present data on silevertinib in recurrent NSCLC and glioblastoma patients. Initial data indicated a 60% Objective Response Rate in frontline NSCLC patients.
Read more →BDTXDocument Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-cl
Black Diamond Therapeutics reported its financial results for Q4 and the full year 2025, indicating continued progress in the clinical development of its drug, silevertinib. The company is set to present Phase 2 trial data for non-small cell lung cancer (NSCLC) in Q2 2026 while preparing to initiate a randomized trial for EGFR altered glioblastoma (GBM). As of December 31, 2025, Black Diamond's cash position stands at approximately $128.7 million, which is anticipated to cover operations into the second half of 2028.
Read more →BDTXBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its financial results for Q4 and full year 2025, highlighting a strong cash position of $128.7 million. The company is on track to present updated clinical data from its Phase 2 trial of silevertinib in non-classical EGFRm NSCLC in Q2 2026 and plans to initiate a randomized Phase 2 trial in newly diagnosed EGFR altered GBM. The company has shown a significant objective response rate in its ongoing trials.
Read more →BDTX▼ -5.3%on this news
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - March 2, 2026
Black Diamond Therapeutics announced its participation in upcoming investor conferences, including the Raymond James BioPharma Conference on April 14, 2026. The company's leadership, including CEO Mark Velleca and CSO Elizabeth Buck, will present at these events. Webcasts will be available for live viewing and archived for 90 days.
Read more →BDTX▼ -22%on this news
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
Black Diamond Therapeutics announced preliminary Phase 2 data for silevertinib in frontline NSCLC patients with non-classical EGFR mutations. The data indicates significant activity against 35 distinct mutations and shows promise for CNS involvement. The company also plans to initiate a randomized Phase 2 trial for silevertinib in newly diagnosed glioblastoma patients in 2026.
Read more →BDTX▼ -22%on this newsshared move
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Black Diamond Therapeutics will host a webcast on December 3, 2025, to present results from its Phase 2 clinical trial of silevertinib, a treatment targeting EGFR-mutant non-small cell lung cancer. The event will also provide a program update. A replay will be available after the live presentation.
Read more →BDTXBlack Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics, a clinical-stage oncology company, announced its participation in upcoming investor conferences. CEO Mark Velleca will present details about the company's innovative MasterKey therapies aimed at treating genetically defined tumors. The presentations will be available via webcast, with replays accessible for 90 days.
Read more →BDTXBlack Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its third quarter 2025 financial results and provided an update on its silevertinib Phase 2 trial for EGFR-mutant NSCLC. The company anticipates sharing clinical data, including overall response rate and preliminary treatment duration, later this quarter. PFS data is expected in the first half of 2026, highlighting the ongoing development of its MasterKey therapies.
Read more →BDTXDocument Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-
Black Diamond Therapeutics reported its financial results for Q3 2025, indicating a net loss of $8.5 million. The company has $135.5 million in cash, expected to sustain operations through Q4 2027. A clinical update from the Phase 2 trial of silevertinib is anticipated later this quarter, with an objective response rate and preliminary treatment duration data to be shared. Additionally, the company is exploring partnership opportunities to advance its development in NSCLC and glioblastoma.
Read more →BDTX▼ -15.2%on this news
Document Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGF
Black Diamond Therapeutics reported its financial results for the second quarter of 2025, highlighting the completion of patient enrollment in the Phase 2 trial of silevertinib for first-line treatment of NSCLC. The company has sufficient cash reserves, reported at approximately $142.8 million, to support its operations until late 2027. Upcoming milestones include the expected release of objective response rate (ORR) and preliminary duration of response (DOR) data in Q4 2025, alongside plans to seek FDA feedback on its development path in 1H 2026.
Read more →BDTX▼ -15.2%on this news
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its financial results for Q2 2025, highlighting the completion of patient enrollment for the Phase 2 trial of silevertinib in non-classical EGFR-mutant NSCLC. The company anticipates revealing objective response rate and preliminary duration of response data in Q4 2025. They are also exploring partnership opportunities to facilitate the pivotal development of silevertinib and plan to meet with the FDA regarding the drug's development pathway in 1H 2026. Black Diamond ended the quarter with $142.8 million in cash, expected to support operations until late 2027.
Read more →BDTX▲ +6.7%on this news· ran to +18% by day 1
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics has reported its financial results for Q1 2025 and provided an update on its clinical trials, particularly for BDTX-1535, aimed at treating patients with EGFR mutations. The company has a strong cash position, estimated to fund operations through Q4 2027. Among the highlights, upcoming Phase 2 data for BDTX-1535 is anticipated by the end of 2025. Additionally, the company has initiated a Phase 0/1 trial for newly diagnosed glioblastoma patients, showing encouraging early results.
Read more →BDTX▲ +6.7%on this news· ran to +18% by day 1
Document Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NS
Black Diamond Therapeutics reported its first quarter financial results for 2025, highlighting a strong cash position of $152.4 million, sufficient to support operations into Q4 2027. The company is progressing in its Phase 2 trial for BDTX-1535, with initial clinical data expected in Q4 2025. Additionally, a partnership with Servier for BDTX-4933 could provide up to $710 million in milestone payments. Despite these positives, uncertainties remain regarding the success of upcoming clinical trials and the risks associated with forward-looking statements.
Read more →BDTXServier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
Servier and Black Diamond Therapeutics have entered a global licensing agreement for BDTX-4933, a targeted therapy for solid tumors. Servier will lead the development and commercialization of BDTX-4933, which is currently in Phase 1 trials. The agreement includes an upfront payment of $70 million and potential milestone payments up to $710 million. This partnership aims to address significant unmet medical needs in patients with RAF/RAS-mutant solid tumors.
Read more →BDTXDocument Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-class
Black Diamond Therapeutics reported its financial results for the fourth quarter and full year of 2024, including key clinical updates. The company anticipates clinical data for its Phase 2 trial of BDTX-1535 targeting EGFR-mutant NSCLC in Q2 2025. Additionally, there will be an expansion into glioblastoma patients in 2025. Financially, Black Diamond ended the year with a solid cash position but reported a net loss of $69.7 million.
Read more →BDTXBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics has reported its financial results for Q4 and the full year of 2024, indicating a net loss of $69.7 million for the year, an improvement from the prior year. Despite the losses, the company's cash position remains strong, with $98.6 million expected to fund operations through Q4 2026. Key upcoming milestones include initial Phase 2 clinical data for BDTX-1535 in NSCLC expected in Q2 2025 and an expansion of trials for glioblastoma in Q1 2025.
Read more →BDTX▲ +8.7%on this news
Document Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad s
Black Diamond Therapeutics reported its Q3 2024 financial results and a corporate update highlighting the encouraging initial Phase 2 data of BDTX-1535 for treating recurrent EGFRm NSCLC. The company showcased promising response rates and durability in patients resistant to existing therapies. With a strong cash position of $112.7 million, Black Diamond anticipates sufficient funds to support operations through 2026. Upcoming milestones include further clinical updates in the first quarter of 2025, alongside a planned FDA meeting to discuss potential registrational paths.
Read more →BDTX▲ +8.7%on this news
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics, Inc. reported third quarter financial results for 2024, demonstrating a focused advancement on its program BDTX-1535 for EGFRm NSCLC. Initial Phase 2 data indicates promising outcomes, including a preliminary overall response rate of 42% among treated patients. The company reported cash reserves of approximately $112.7 million, projected to sustain operations through mid-2026, while also disclosing plans for corporate restructuring to optimize resource allocation. Upcoming clinical updates and regulatory feedback are anticipated in 2025.
Read more →BDTXBlack Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-49
Black Diamond Therapeutics has announced a major restructuring plan aimed at focusing its resources on BDTX-1535, a candidate for treating EGFRm NSCLC. This move is expected to extend the company's cash runway into Q2 2026, bolstering the development efforts for this promising therapy. In Q1 2025, Black Diamond plans to release initial Phase 2 data for BDTX-1535, potentially paving the way for significant advancements in the treatment landscape. However, the company will deprioritize the BDTX-4933 program and will undergo management changes as part of the restructuring.
Read more →BDTX▼ -5.5%on this news
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C7
Black Diamond Therapeutics has announced initial Phase 2 data indicating significant anti-tumor activity of BDTX-1535 for patients with recurrent EGFRm non-small cell lung cancer (NSCLC). The drug showed a preliminary overall response rate of 42% in the 19 patients treated, with notable durability in responses. The trial, which began in August 2023, continues to enroll patients across different cohorts, and the company anticipates regulatory feedback on registration pathways in the future.
Read more →BDTX▼ -5.5%on this newsshared move
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Black Diamond Therapeutics will host a webcast presentation on September 23, 2024, to share initial Phase 2 clinical trial data for BDTX-1535, targeting recurrent EGFRm non-small cell lung cancer (NSCLC). The event aims to inform investors of the latest developments in the company’s therapy pipeline. BDTX-1535 is designed to penetrate the brain and effectively address oncogenic mutations.
Read more →BDTX▼ -12.4%on this news· ran to -23% by day 3
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
Black Diamond Therapeutics presented findings at the ESMO Congress 2024 regarding the treatment outcomes of newly diagnosed NSCLC patients with non-classical EGFR mutations. The analysis, based on 3,276 cases, shows that current treatment practices are heterogeneous, with many patients experiencing quick discontinuation of therapies like osimertinib and afatinib. The company aims to address the significant unmet need with its candidate BDTX-1535, which is designed specifically for patients with these mutations. Initial Phase 2 data for this therapy is expected in early 2025.
Read more →BDTX▼ -5.6%on this news
Document Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Initial Phase 2 data of BDTX-1535 in 2L 3L patients with EGFRm NSCLC on track for later in Q3 2024 On track
Black Diamond Therapeutics has reported its financial results for the second quarter of 2024, showcasing a cash position of $123 million. The company is on track to announce initial Phase 2 data for its drug BDTX-1535 targeting EGFR mutant NSCLC patients later in Q3 2024. Additionally, data for BDTX-4933 targeting KRAS mutant NSCLC is expected in Q4 2024. Upcoming presentations at notable conferences aim to address significant unmet medical needs in cancer therapies.
Read more →BDTX▼ -5.6%on this news
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its financial results for Q2 2024, highlighting a net loss of $19.9 million and cash reserves of $123.0 million. The company is on track to announce initial Phase 2 data for its lead product BDTX-1535 in non-small cell lung cancer (NSCLC) patients in Q3 2024 and Q1 2025. Additionally, they will present real-world evidence at the upcoming 2024 ESMO Congress, illustrating high unmet medical needs in patients with non-classical EGFR mutations in NSCLC. The report reflects strategic advancements despite ongoing financial losses.
Read more →BDTXBlack Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics recently presented promising clinical data for BDTX-1535 at the 2024 ASCO Annual Meeting, highlighting the drug's favorable safety profile and encouraging anti-tumor activity in patients with recurrent glioblastoma (GBM). Data from a Phase 1 trial demonstrated significant brain penetrance and longer than expected treatment durations. Additionally, initial results from a Phase 0/1 trial revealed that BDTX-1535 achieves target drug concentrations in brain tumor tissues, which bodes well for its potential efficacy. These findings support the continued development of BDTX-1535 as a targeted therapy for GBM.
Read more →BDTXDocument Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Initial Phase 2 data of BDTX-1535 in 2L 3L EGFRm NSCLC patients on track for Q3 2024 Enrollment ongoing in Ph
Black Diamond Therapeutics reported its first-quarter 2024 financial results and provided an update on its clinical developments. The company is on track to release initial Phase 2 data on BDTX-1535 for EGFR mutant NSCLC patients in Q3 2024, while enrollment in another Phase 2 trial for first-line patients continues. The company also highlighted its cash position of $115.2 million as of March 31, 2024, which they believe will support operations until at least Q3 2025.
Read more →BDTXBlack Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its financial results for Q1 2024, highlighting progress in the development of its BDTX-1535 therapy for non-small cell lung cancer (NSCLC). Initial Phase 2 data is expected to be released in Q3 2024, with ongoing studies enrolling patients to assess the drug's efficacy. The company has a solid cash position of $115.2 million to support operations through Q3 2025, despite reporting a net loss of $18.2 million for the quarter. Additionally, recent presentations at major conferences reflect the promising potential of BDTX-1535 across various lines of therapy.
Read more →BDTXBlack Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics has announced its participation at the 2024 ASCO Annual Meeting, set to be held from May 31 to June 4 in Chicago, IL. They will present data on BDTX-1535, an oral, fourth-generation covalent EGFR inhibitor, specifically targeting patients with recurrent glioblastoma. The presentation will provide results from a Phase 1 dose escalation trial, as well as a Phase 0/1 'trigger' trial. The outcomes may offer insights into the efficacy of BDTX-1535 in treating brain and lung cancers.
Read more →BDTX▲ +11.8%on this news
Black Diamond Therapeutics Announces Changes to Board of Directors CAMBRIDGE, Mass .
Black Diamond Therapeutics has announced changes to its Board of Directors, appointing Shannon Campbell and Prakash Raman, Ph.D., while Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., stepped down. The appointments are expected to strengthen the board's expertise in oncology as the company advances BDTX-1535, a fourth-generation EGFR inhibitor, through Phase 2 development. The leadership changes were made effective on April 10, 2024.
Read more →BDTX▲ +5.7%on this newsshared move
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Black Diamond Therapeutics presented compelling data on BDTX-1535 at the 2024 AACR Annual Meeting, highlighting its ability to target a broad range of EGFR mutations in non-small cell lung cancer (NSCLC). This fourth-generation TKI has demonstrated efficacy against both classical and non-classical mutations, including the drug-resistant C797S mutation. Real-world evidence indicates that non-classical mutations are increasingly prevalent, with BDTX-1535 positioned to address these mutations effectively. The company is currently advancing BDTX-1535 in a Phase 2 trial for NSCLC, with promising initial results expected in late 2024.
Read more →BDTX▼ -5.5%on this news· ran to +20% by day 3
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics announced its fourth-quarter and full-year 2023 financial results, highlighting significant progress in its ongoing clinical trials. The company initiated dosing for the first patient in a Phase 2 trial of BDTX-1535 for non-small cell lung cancer. Additionally, Black Diamond is scheduled to release further clinical data in 2024, showcasing its potential as a leader in targeted therapies for oncogenic mutations. The company also reported a healthy cash position, enabling continued operational funding into mid-2025.
Read more →BDTX▼ -5.5%on this news· ran to +20% by day 3
Document Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCL
Black Diamond Therapeutics has reported its fourth quarter and full year 2023 financial results, highlighting the dosing of the first patient in a Phase 2 trial of BDTX-1535 for non-classical EGFRm non-small cell lung cancer (NSCLC). The company maintains a strong cash position of approximately $131.4 million, expected to sustain operations into Q2 2025. Key forthcoming milestones include data releases in 2024 for both BDTX-1535 and the BDTX-4933 program, which demonstrates potential clinical benefits across multiple treatment lines. While the outlook is generally positive, the company faces challenges including substantial net losses and ongoing operational costs.
Read more →BDTXBlack Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
Black Diamond Therapeutics announced an upcoming oral presentation at the AACR Annual Meeting 2024, scheduled for April 7, 2024. The presentation will focus on BDTX-1535, a fourth-generation MasterKey inhibitor that targets various oncogenic EGFR mutations in non-small cell lung cancer (NSCLC). It aims to provide insights on the evolving landscape of EGFR mutations, emphasizing the significance of 'non-classical' mutations. Additionally, the discussion will highlight ongoing trials related to BDTX-1535 in NSCLC and glioblastoma.
Read more →BDTXBlack Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Black Diamond Therapeutics, a clinical-stage oncology firm, announced that CEO Mark A. Velleca will participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference on March 6, 2024. The event will take place in Boston, MA, and a live webcast will be made available. The company is advancing MasterKey therapies targeting specific oncogenic mutations that aim to improve treatment for genetically defined cancers.
Read more →BDTXBlack Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track Desi
Black Diamond Therapeutics has provided a corporate update outlining its clinical development plans and expected milestones for 2024. Notably, the FDA's recent feedback allows the company to initiate a Phase 2 trial cohort for BDTX-1535 in the first-line treatment of non-classical EGFR mutant NSCLC, as well as a Fast Track designation for the drug in a second-line setting. The company anticipates key data readouts from ongoing trials, with results expected in 2024 for both BDTX-1535 and BDTX-4933. Financially, Black Diamond expects to maintain sufficient cash resources to fund its operations through mid-2025.
Read more →BDTX▼ -9%on this news
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM Initial results show promising clinical activity in heavily pretreated patients 22 patie
Black Diamond Therapeutics has released topline results from their Phase 1 dose escalation trial of BDTX-1535 for recurrent glioblastoma (GBM). The study, involving heavily pretreated patients, reported that out of 22 evaluable patients, significant clinical activity was observed with partial responses and stable disease noted. DBTX-1535 demonstrated a favorable safety profile with no new adverse safety signals. The findings support the potential of BDTX-1535 as a treatment option for GBM, especially as current approved therapies are lacking.
Read more →BDTXDocument Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety pro
Black Diamond Therapeutics announced its third quarter 2023 financial results, highlighting the progress of its lead program BDTX-1535 with favorable Phase 1 clinical trial data presented at the AACR-NCI-EORTC conference. The data demonstrated durable anti-tumor activity in NSCLC patients and a favorable safety profile. The company also reported a cash position believed sufficient to fund operations into the first half of 2025 and outlined upcoming milestones for its pipeline, including initial data for BDTX-4933 targeting KRAS, NRAS, and BRAF mutations. Overall, the report reflects significant advancements in Black Diamond’s oncology therapeutic developments.
Read more →BDTXBlack Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its third quarter 2023 financial results, highlighting significant progress with its lead program BDTX-1535 in NSCLC and ongoing enrollment in clinical trials. Positive Phase 1 data demonstrate the drug's durable responses and safety profile, prompting further trials for various patient cohorts. The company reported a cash position of $144.3 million, projected to sustain operations up to mid-2025, despite a net loss of $23 million for the quarter. Upcoming milestones include further data on BDTX-1535 and progress with its newly initiated BDTX-4933 trial.
Read more →BDTX▼ -6.6%on this news
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
Black Diamond Therapeutics presented data indicating durable responses in patients with non-small cell lung cancer (NSCLC) from its Phase 1 trial of BDTX-1535. The results showed that the treatment has the potential to address a significant unmet medical need in patients who have progressed on previous therapies. No new safety concerns were raised, and the drug demonstrated substantial efficacy, including circulating tumor DNA clearance. Initial expansion cohort data is expected in 2024.
Read more →BDTX▼ -5.6%on this news
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Black Diamond Therapeutics has announced that it will present key preclinical and clinical data at the AACR-NCI-EORTC International Conference in Boston from October 11-15, 2023. The three presentations will focus on the Phase 1 clinical trial of BDTX-1535, an oral EGFR inhibitor for non-small cell lung cancer (NSCLC), as well as preclinical data for BDTX-4933. BDTX-1535 shows potential in addressing a wide range of mutations affecting NSCLC and glioblastoma multiforme (GBM) patients. The ongoing trial is exploring its effectiveness in both NSCLC and GBM contexts.
Read more →BDTXBlack Diamond Therapeutics Announces CEO Transition Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and
Black Diamond Therapeutics has announced the appointment of Mark Velleca as the new Chief Executive Officer, succeeding David M. Epstein, who co-founded the company. Velleca, who has been the Chairman of the Board since 2022, brings a wealth of experience from his prior role as CEO at G1 Therapeutics and other leadership positions in the industry. The company aims to advance its clinical stage programs, specifically BDTX-1535 and BDTX-4933, as it transitions into a new phase of growth. This leadership change signifies a strategic shift as Black Diamond focuses on enhancing its pipeline and creating value for stakeholders.
Read more →BDTXBlack Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
Black Diamond Therapeutics has commenced dosing the first patients in mutation matched expansion cohorts of its Phase 1 clinical trial investigating BDTX-1535 for non-small cell lung cancer (NSCLC). This fourth-generation EGFR TKI is being evaluated specifically in patients with intrinsic driver and acquired resistance mutations. The trial aims to assess the objective response rate and efficacy of BDTX-1535, addressing an unmet medical need for targeted therapies in NSCLC. The company will also present its dose escalation data at the upcoming AACR-NCI-EORTC Conference in October 2023.
Read more →BDTXDocument Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Announced initial clinical data from dose-escalation portion of Phase 1 clinical trial of BDTX-1535, an EGFR
Black Diamond Therapeutics reported its Q2 2023 financial results, highlighting positive early clinical data from its Phase 1 trial of BDTX-1535, an EGFR MasterKey inhibitor. The data indicates a favorable tolerability profile and proof of clinical activity in NSCLC patients with specific mutations. Moreover, the company's recent underwritten public offering provided significant capital, expected to sustain operations through mid-2025. Although there were some instances of dose limiting toxicity and a net loss reported, the overall outlook remains optimistic with upcoming milestones on the horizon.
Read more →BDTXBlack Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its second quarter 2023 financial results, indicating advancements in its clinical program for BDTX-1535, an EGFR MasterKey inhibitor. The initial clinical data demonstrated favorable tolerability and activity in NSCLC patients. Additionally, the company secured $75 million from a public offering, ensuring adequate funding through the first half of 2025. Despite a net loss of $20 million, Black Diamond remains optimistic about future regulatory discussions and continued advancements in its pipeline.
Read more →BDTXBlack Diamond Therapeutics Announces Pricing of Public Offering of Common Stock
Black Diamond Therapeutics announced a public offering of 15 million shares priced at $5.00 each, expected to raise approximately $75 million before expenses. The offering is set to close around July 5, 2023, pending customary conditions. Piper Sandler is the sole book-running manager, while Wedbush PacGrow serves as the lead manager for the offering. The company aims to utilize the funds to support the development of its precision oncology therapies targeting specific oncogenic mutations.
Read more →BDTX▼ -7.3%on this news· ran to -24% by day 3shared move
Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock
Black Diamond Therapeutics has announced a proposed public offering of $75 million in common stock, with an additional option for underwriters to purchase $11.25 million more. The offering is meant to support the company's clinical-stage precision oncology developments. Details will be provided following SEC regulations, as the terms of the offering depend on market conditions. This move signifies the company's commitment to advancing its innovative therapies targeting genetically defined cancers.
Read more →BDTX▲ +235.9%on this newsshared move
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families BDTX-1535, an epidermal growt
Black Diamond Therapeutics announced promising initial data from the Phase 1 clinical trial of BDTX-1535, an investigational EGFR MasterKey inhibitor for non-small cell lung cancer (NSCLC). The results demonstrated anti-tumor activity in patients with various EGFR mutations, including those resistant to osimertinib. BDTX-1535's favorable safety profile and unique mechanism of targeting multiple mutation families could position it as a significant treatment option. The company aims to work with the FDA towards a recommended Phase 2 dose selection and potential accelerated approval for NSCLC patients.
Read more →BDTX▲ +5.3%on this news
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer
Black Diamond Therapeutics has announced the promotion of Melanie Morrison to Chief Development Officer. Her new role will involve leading clinical operations and regulatory affairs, building on her significant experience in oncology development. Under her leadership since joining in 2022, the company has advanced its clinical programs, notably the Phase 1 trial of BDTX-1535. The company's focus remains on developing therapies targeting oncogenic mutations in genetically defined cancers.
Read more →BDTX▲ +8.8%on this news
Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference
Black Diamond Therapeutics, a clinical-stage precision oncology company, announced its participation in the Jefferies Healthcare Conference on June 9, 2023. During the event, CEO David M. Epstein will present an overview of their MasterKey programs, which include BDTX-1535 and BDTX-4933. The company focuses on targeting oncogenic mutations in genetically defined cancers and aims to advance its therapeutic pipeline using its innovative drug discovery engine.
Read more →BDTX▼ -5.2%on this news
Document Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey
Black Diamond Therapeutics has released its financial results for the first quarter of 2023, highlighting significant progress in its clinical programs. The company is poised to provide a clinical update on its Phase 1 trial of BDTX-1535 later this year and has received FDA clearance for its BDTX-4933 trial, with first patient dosing expected soon. Additionally, Black Diamond has nominated a new candidate, BDTX-4876, for development in its FGFR selective inhibitor program. Despite a net loss reported for the quarter, the company's cash reserves are expected to sustain operations into the third quarter of 2024.
Read more →BDTX▼ -5.2%on this news
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its Q1 2023 financial results and provided a corporate update, highlighting significant advancements in its clinical pipeline. The company expects to release a clinical update for the BDTX-1535 Phase 1 trial in the latter half of 2023 and is preparing to initiate the BDTX-4933 trial. Additionally, Black Diamond announced the selection of BDTX-4876 as a development candidate. The company maintains a strong financial position with over $103 million, which is projected to fund operations into 2024.
Read more →BDTXBlack Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
Black Diamond Therapeutics, a precision oncology company, will present its MasterKey programs during the Stifel 2023 Targeted Oncology Days on April 25, 2023. The presentation will be led by CEO David M. Epstein, focusing on programs including BDTX-1535 and BDTX-4933. These therapies aim to target oncogenic driver mutations, addressing significant unmet needs in genetically defined cancers. A live webcast of the presentation will be available on the company's website.
Read more →BDTXBlack Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting
Black Diamond Therapeutics presented updates at the 2023 AACR Annual Meeting regarding its pipeline, focusing on BDTX-1535 and BDTX-4933. The ongoing Phase 1 studies for BDTX-1535 target non-small cell lung cancer (NSCLC) and glioblastoma (GBM) with promising preliminary data. BDTX-4933, designed to inhibit RAF signaling in various mutations, will enter clinical trials in Q2 2023. The company's MasterKey therapies may pave the way for advancements in treating genetically defined cancers.
Read more →BDTX▼ -13.7%on this news
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported its financial results for Q4 and the full year of 2022, indicating a reduced cash reserve of $122.8 million. The company received FDA approval for its IND application for BDTX-4933 and is on track to provide a clinical update for BDTX-1535 in the latter half of 2023. New preclinical data highlighting the effectiveness of its MasterKey programs were presented at a key oncology symposium. Despite recent advancements, the company has faced significant net losses and reduced cash flow.
Read more →BDTX▼ -13.7%on this news
Document Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of
Black Diamond Therapeutics reported its financial results for Q4 and the full year of 2022, highlighting progress in its clinical trials. The FDA granted IND clearance for BDTX-4933, paving the way for its Phase 1 trial expected in 2023. The company is also on track to announce updates on the BDTX-1535 trial later in the year. Despite a significant net loss in 2022, Black Diamond maintains a solid cash position to support ongoing operations through 2024.
Read more →BDTX▼ -9.3%on this news
Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
Black Diamond Therapeutics, a clinical-stage precision oncology company, announced that its CEO, David M. Epstein, will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023. The company is developing MasterKey therapies targeting oncogenic mutations in genetically defined cancers, with a focus on overcoming resistance and minimizing toxicities. Their lead programs include BDTX-1535 for non-small cell lung cancer and glioblastoma, and BDTX-4933 targeting RAF mutations in solid tumors.
Read more →BDTXBlack Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Black Diamond Therapeutics (Nasdaq: BDTX) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023. CEO David M. Epstein, Ph.D., will provide an update on the company's progress and its pipeline of MasterKey therapies targeting oncogenic mutations. Their leading clinical programs include BDTX-1535 for NSCLC and glioblastoma, as well as BDTX-4933 for solid tumors. The presentation will be accessible via a live webcast, with an archived version available for 90 days.
Read more →BDTXBlack Diamond Therapeutics Announces Changes to Board of Directors CAMBRIDGE, Mass. and
Therapeutics Announces Changes to Board of Directors CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today a
Read more →BDTXBlack Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company - $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and
Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK, December 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a pr
Read more →BDTXDocument Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Presented new data at the 34 th EORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Presented new data at the 34th EORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity of BDTX-1535 and BDTX-4933 across multiple families of oncogenic muta
Read more →BDTXBlack Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Presented new data at the 34th EORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity of BDTX-1535 and BDTX-4933 across multiple families of oncogenic mutations while sparing wild type; both MasterKey therapies demonstrate key attributes of next generation s
Read more →BDTXBlack Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic EGFR conformations to drive tumor cell growth in GBM and NSCLC BDTX-1535 demonstrated potent systemic and CNS anti-tumor activity and survival benefit in multip
Read more →BDTXDocument Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Strengthened leadership team with appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer Advan
Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Strengthened leadership team with appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer Advanced MasterKey therapy pipeline with first patient dosed in Phase 1
Read more →BDTXBlack Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Strengthened leadership team with appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer Advanced MasterKey therapy pipeline with first patient dosed in Phase 1 global study of BDTX-1535, and continued IND-enabling studies of BDTX-4933 Cash, cash equivalents and i
Read more →BDTXBlack Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
CAMBRIDGE, Mass. and NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer,
Read more →BDTXBlack Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer,
Read more →BDTXBlack Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer
- Dr. Yurasov brings over 25 years of experience in oncology drug development and regulatory expertise - CAMBRIDGE, Mass. and NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discove
Read more →BDTX▲ +5.9%on this news
Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass. and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer,
Read more →BDTXBlack Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine
- Peer-reviewed publication highlights 22 new oncogenic HER2 driver mutations identified and experimentally validated with MAP discovery engine - CAMBRIDGE, Mass. and NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology
Read more →BDTX▼ -7.9%on this newsshared move
Document Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Dosed first patient in Phase 1 Study of BDTX-1535 for the treatment of glioblastoma multiforme (GBM) and non-
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Dosed first patient in Phase 1 Study of BDTX-1535 for the treatment of glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC) including those with central nervous
Read more →BDTX▼ -7.9%on this newsshared move
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Dosed first patient in Phase 1 Study of BDTX-1535 for the treatment of glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC) including those with central nervous system (CNS) tumors; clinical update expected in 2023 Continued strategic focus on development of BDTX
Read more →BDTXBlack Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment - Strategic areas of focus on development of BDTX-1535 and BDTX-4933 as well as MAP platform enabled small molecule drug discovery ef
Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment CAMBRIDGE, Mass. and NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developm
Read more →BDTXBlack Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer
- Clinical update expected in second half of 2023 - CAMBRIDGE, Mass. and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today ann
Read more →BDTX▲ +14.1%on this news
Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors CAMBRIDGE, Mass. and
Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors CAMBRIDGE, Mass. and NEW YORK, April 7, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Mast
Read more →BDTX▲ +14.1%on this news
Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference
CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer
Read more →BDTXDocument Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update IND allowed by U.S. FDA and Phase 1 study of BDTX-1535 initiated for the treatment of GBM and
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update IND allowed by U.S. FDA and Phase 1 study of BDTX-1535 initiated for the treatment of GBM and NSCLC including those with CNS metastases Preclinical data demonstr
Read more →BDTXBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
IND allowed by U.S. FDA and Phase 1 study of BDTX-1535 initiated for the treatment of GBM and NSCLC including those with CNS metastases Preclinical data demonstrating the potential of MasterKey programs BDTX-1535, CNS-BRAF (BDTX-4933), and FGFR presented at AACR-NCI-EORTC (ANE)
Read more →BDTXBlack Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
CAMBRIDGE, Mass. and NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer
Read more →BDTX▼ -5.6%on this news
Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer
CAMBRIDGE, Mass. and NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Elizabeth Montgomery as its
Read more →BDTX▲ +13.3%on this news
Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer
CAMBRIDGE, Mass. and NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that the U.S. Food and Drug Administration (FDA
Read more →BDTX▼ -11.8%on this newsshared move
Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022 - Company announces IND submission for BDTX-1535 for the treatment of GBM and NSCLC including those with CNS tumors; - Company to
Therapeutics Announces Strategic Priorities and Expected Milestones for 2022 - Company announces IND submission for BDTX-1535 for the treatment of GBM and NSCLC including those with CNS tumors; - Company to enroll additional patients into MasterKey-01 Phase 1 safety expansion
Read more →BDTXBlack Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer,
Read more →BDTXDocument Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Black Diamond continues preparation for initiation of the Phase 2 portion of MasterKey-01 study of BDTX-189 t
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Black Diamond continues preparation for initiation of the Phase 2 portion of MasterKey-01 study of BDTX-189 this year Pre-clinical data from BDTX-1535, BRAF, and FGFR programs
Read more →BDTXBlack Diamond Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer,
Read more →BDTXBlack Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Black Diamond continues preparation for initiation of the Phase 2 portion of MasterKey-01 study of BDTX-189 this year Pre-clinical data from BDTX-1535, BRAF, and FGFR programs presented at AACR-NCI-EORTC (ANE) International Conference Strategic partnership established with Open
Read more →BDTXBlack Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass. and NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the presentation of preclinical data for three
Read more →BDTX▼ -6.6%on this news
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass. and NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the presentation of pre-clinical data for thre
Read more →BDTXBlack Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer
Read more →BDTXBlack Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform
Strategic partnership between Black Diamond and OpenEye aims to accelerate drug discovery efforts through cloud-based molecular dynamics technology CAMBRIDGE, Mass. and SANTA FE, N.M., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, a precision oncology medicine c
Read more →BDTXDocument Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 presented at ASCO Annual Mee
Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 presented at ASCO Annual Meeting on track to initiate Phase 2 portion of MasterKey-01 study in s
Read more →BDTXBlack Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 presented at ASCO Annual Meeting; on track to initiate Phase 2 portion of MasterKey-01 study in second half of 2021 Pre-clinical data for BDTX-1535 presented at AACR Annual Meeting; program on track
Read more →BDTXBlack Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors CAMBRIDGE, Mass. and
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors CAMBRIDGE, Mass. and NEW YORK, August 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discover
Read more →BDTXBlack Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations Once-daily (QD) dose escalation completed; pharma
Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and p
Read more →BDTXBlack Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial
Company to host conference call on Wednesday, May 19, 2021 at 6:00 PM ET CAMBRIDGE, Mass. and NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molec
Read more →BDTXDocument Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update Patient enrollment and dosing in the Phase 1 2 clinical trial of BDTX-189 continue to track in line with proj
Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update Patient enrollment and dosing in the Phase 1 2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on
Read more →BDTXBlack Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initial Phase 1 clinical pharmacokinetic (PK), safety, and pre
Read more →BDTXBlack Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology
Initial pharmacokinetic (PK), safety, and preliminary efficacy data from Phase 1 dose-escalation portion of MasterKey-01 clinical trial to be presented CAMBRIDGE, Mass. and NEW YORK, April 28, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision
Read more →BDTXBlack Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass. and NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the presentation of preclinica
Read more →BDTXBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initiation of safety expansion cohort anticipated in the secon
Read more →BDTXDocument Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Patient enrollment and dosing in the Phase 1 2 clinical trial of BDTX-189 continue to track in
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Patient enrollment and dosing in the Phase 1 2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalat
Read more →BDTXBlack Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass. and NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that pre-clinical data on
Read more →BDTXBlack Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021
CAMBRIDGE, Mass. and NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-c
Read more →BDTXBlack Diamond Therapeutics to Present at the BMO Biopharma Spotlight Series
CAMBRIDGE, Mass. and NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chi
Read more →BDTXBlack Diamond Therapeutics Announces Appointment of Oncology Clinical Development Veteran Dr. Kapil Dhingra to Board of Directors CAMBRIDGE, Mass. and
Black Diamond Therapeutics Announces Appointment of Oncology Clinical Development Veteran Dr. Kapil Dhingra to Board of Directors CAMBRIDGE, Mass. and NEW YORK, January 20, 2021 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering t
Read more →BDTXBlack Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chi
Read more →BDTXBlack Diamond Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chi
Read more →BDTXBlack Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting
BDTX-1535 nominated as development candidate with IND-enabling studies underway Pre-clinical data support novel and differentiated approach in GBM CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision onco
Read more →BDTXBlack Diamond Therapeutics to Present at the Jefferies 2020 Virtual London Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chi
Read more →BDTXDocument Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Continued to enroll and dose patients in Phase 1 2 clinical trial of BDTX-189, with Phase 1 portion on track
Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Continued to enroll and dose patients in Phase 1 2 clinical trial of BDTX-189, with Phase 1 portion on track to complete by first half of 2021 Strengthened Board of Directors w
Read more →BDTXBlack Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Continued to enroll and dose patients in Phase 1/2 clinical trial of BDTX-189, with Phase 1 portion on track to complete by first half of 2021 Strengthened Board of Directors with appointment of Robert A. Ingram as Chairman Bolstered executive team with appointment of Rachel Hu
Read more →BDTXBlack Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium
CAMBRIDGE, Mass. and NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-cl
Read more →BDTXBlack Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium
CAMBRIDGE, Mass. and NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that pre-clinical data on
Read more →BDTXBlack Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board CAMBRIDGE, Mass. and
Black Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board CAMBRIDGE, Mass. and NEW YORK, September 29, 2020 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the d
Read more →BDTXBlack Diamond Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Ch
Read more →BDTXBlack Diamond Therapeutics Announces the Appointment of Rachel Humphrey, M.D., as Chief Medical Officer
CAMBRIDGE, Mass. and NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Rachel
Read more →BDTXDocument Black Diamond Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Obtained U.S. FDA Fast Track designation for BDTX-189 for the treatment of adult patients with a solid tumor
Black Diamond Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Obtained U.S. FDA Fast Track designation for BDTX-189 for the treatment of adult patients with a solid tumor harboring an allosteric HER2 mutation or an EGFR or HER2 Exon 20 in
Read more →BDTXBlack Diamond Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
• Obtained U.S. FDA Fast Track designation for BDTX-189 for the treatment of adult patients with a solid tumor harboring an allosteric HER2 mutation or an EGFR or HER2 Exon 20 insertion mutation • Continued to enroll and dose patients in Phase 1/2 clinical trial of BDTX-189, wi
Read more →BDTXBlack Diamond Therapeutics Announces the Appointment of Fang Ni as Chief Business Officer
CAMBRIDGE, Mass. and NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Fang Ni
Read more →BDTXBlack Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation
CAMBRIDGE, Mass. and NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that the U.S. Food and Dru
Read more →BDTXBlack Diamond Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chi
Read more →BDTXBlack Diamond Therapeutics to Present at the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, May 27, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chie
Read more →BDTXBlack Diamond Therapeutics Announces Accepted Abstract for Lead Product Candidate BDTX-189 at American Society of Clinical Oncology 2020
CAMBRIDGE, Mass. and NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that the design of MasterKe
Read more →BDTXBlack Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update
Cash and cash equivalents of $357.2 million as of March 31, 2020, believed to be sufficient to fund operations into 2023 Completed initial public offering in February 2020 raising $231.3 million in gross proceeds Continued to enroll and dose patients in Phase 1/2 clinical trial
Read more →BDTXDocument Black Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update Cash and cash equivalents of $357.2 million as of
Black Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update Cash and cash equivalents of $357.2 million as of March 31, 2020, believed to be sufficient to fund operations into 2023 Completed initial public offering in February 2020 raising $231.
Read more →BDTXBlack Diamond Therapeutics to Present at the Bank of America Global Research Health Care Conference 2020
CAMBRIDGE, Mass. and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chie
Read more →BDTXDocument Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update U.S. Food and Drug Administration allowed Black Diamond's investigational new drug application for its
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update U.S. Food and Drug Administration allowed Black Diamond's investigational new drug application for its lead product candidate BDTX-189 in December Company initiated Phase
Read more →BDTXBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
U.S. Food and Drug Administration allowed Black Diamond’s investigational new drug application for its lead product candidate BDTX-189 in December; Company initiated Phase 1/2 clinical trial and has subsequently started enrolling and dosing patients Cash and cash equivalents of
Read more →BDTXBlack Diamond Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
CAMBRIDGE, Mass. and NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced its President and Chief Ex
Read more →BDTXBlack Diamond Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass. and NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the closing of its initial
Read more →BDTXBlack Diamond Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. and NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the pricing of its initial
Read more →Competitive Position
How BDTX ranks across every disease it competes inCompetitive Position is a premium feature
See how BDTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial